JPWO2019152955A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019152955A5
JPWO2019152955A5 JP2020564037A JP2020564037A JPWO2019152955A5 JP WO2019152955 A5 JPWO2019152955 A5 JP WO2019152955A5 JP 2020564037 A JP2020564037 A JP 2020564037A JP 2020564037 A JP2020564037 A JP 2020564037A JP WO2019152955 A5 JPWO2019152955 A5 JP WO2019152955A5
Authority
JP
Japan
Prior art keywords
substituted
pharmaceutically acceptable
amide
alkoxy
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020564037A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512953A5 (https=
JP2021512953A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/016557 external-priority patent/WO2019152955A1/en
Publication of JP2021512953A publication Critical patent/JP2021512953A/ja
Publication of JP2021512953A5 publication Critical patent/JP2021512953A5/ja
Publication of JPWO2019152955A5 publication Critical patent/JPWO2019152955A5/ja
Priority to JP2024007282A priority Critical patent/JP2024054873A/ja
Pending legal-status Critical Current

Links

JP2020564037A 2018-02-02 2019-02-04 ゲムシタビンモノホスフェートの小分子薬物コンジュゲート Pending JP2021512953A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024007282A JP2024054873A (ja) 2018-02-02 2024-01-22 ゲムシタビンモノホスフェートの小分子薬物コンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862625820P 2018-02-02 2018-02-02
US62/625,820 2018-02-02
PCT/US2019/016557 WO2019152955A1 (en) 2018-02-02 2019-02-04 Small molecule drug conjugates of gemcitabine monophosphate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024007282A Division JP2024054873A (ja) 2018-02-02 2024-01-22 ゲムシタビンモノホスフェートの小分子薬物コンジュゲート

Publications (3)

Publication Number Publication Date
JP2021512953A JP2021512953A (ja) 2021-05-20
JP2021512953A5 JP2021512953A5 (https=) 2022-02-14
JPWO2019152955A5 true JPWO2019152955A5 (https=) 2022-02-14

Family

ID=65494554

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564037A Pending JP2021512953A (ja) 2018-02-02 2019-02-04 ゲムシタビンモノホスフェートの小分子薬物コンジュゲート
JP2024007282A Pending JP2024054873A (ja) 2018-02-02 2024-01-22 ゲムシタビンモノホスフェートの小分子薬物コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024007282A Pending JP2024054873A (ja) 2018-02-02 2024-01-22 ゲムシタビンモノホスフェートの小分子薬物コンジュゲート

Country Status (17)

Country Link
US (1) US11760773B2 (https=)
EP (1) EP3746134A1 (https=)
JP (2) JP2021512953A (https=)
KR (1) KR20200118827A (https=)
CN (1) CN112135634A (https=)
AU (1) AU2019216531A1 (https=)
BR (1) BR112020015745A2 (https=)
CA (1) CA3091027A1 (https=)
CL (1) CL2020002022A1 (https=)
CO (1) CO2020010970A2 (https=)
EA (1) EA202091856A1 (https=)
IL (1) IL276436A (https=)
MX (1) MX2020008188A (https=)
PE (1) PE20210367A1 (https=)
PH (1) PH12020551182A1 (https=)
SG (1) SG11202007386RA (https=)
WO (1) WO2019152955A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210367A1 (es) * 2018-02-02 2021-02-26 Maverix Oncology Inc Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU389090A1 (ru) 1971-05-17 1973-07-05 Ташкентский государственный медицинский институт Библиотека
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US5229272A (en) 1989-04-25 1993-07-20 Igen, Inc. Catalytic antibody components
ZA859008B (en) 1984-12-04 1987-07-29 Lilly Co Eli The treatment of tumors in mammals
ATE92499T1 (de) 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
DE3786834T2 (de) 1986-04-30 1994-03-03 Otsuka Pharma Co Ltd 5-Fluoro-Uracil-Derivate.
US6702705B1 (en) 1988-05-04 2004-03-09 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
EP0418292A4 (en) 1988-05-25 1991-09-25 Research Corporation Technologies, Inc Phosphoramides useful as antitumor agents
DE3834860A1 (de) 1988-10-13 1990-04-19 Basf Ag Heterocyclisch substituierte alkoxycumarine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel
DE3834861A1 (de) 1988-10-13 1990-04-19 Basf Ag Arylalkoxycumarine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel
US6258360B1 (en) 1989-05-04 2001-07-10 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
US6060592A (en) 1990-01-11 2000-05-09 Isis Pharmaceuticals, Inc. Pyrimidine nucleoside compounds and oligonucleoside compounds containing same
US5401838A (en) 1992-06-22 1995-03-28 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
DK0702683T3 (da) 1993-06-08 2004-02-02 Cancer Rec Tech Ltd 06-substituerede guaninderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i behandling af tumorceller
DK0795334T3 (da) 1996-03-12 2006-06-06 Sanofi Aventis Deutschland Nye prodrugs til behandling af tumorer og betændelsessygdomme
WO1998011484A1 (fr) 1996-09-13 1998-03-19 Hitachi, Ltd. Processeur de commande a memoire d'historique
ATE236188T1 (de) 1997-01-24 2003-04-15 Conpharma As Gemcitabin-derivate
NZ330360A (en) 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
TW434252B (en) 1997-07-23 2001-05-16 Univ Georgia Res Found Process for the preparation of 2'-fluoro-5-methyl-β-L-arabino-furanosyluridine
EP1051383B1 (en) 1998-02-06 2004-07-28 De Montfort University Hydroxylation activated prodrugs
AU2531599A (en) 1998-02-12 1999-08-30 De Montfort University Hydroxylation activated drug release
DE19834751A1 (de) 1998-08-01 2000-02-03 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
US6175001B1 (en) 1998-10-16 2001-01-16 The Scripps Research Institute Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same
YU68102A (sh) 2000-03-16 2006-01-16 F. Hoffmann-La Roche Ag. Derivati karboksilne kiseline kao ip antagonisti
GB0007401D0 (en) 2000-03-27 2000-05-17 Cancer Res Campaign Tech Substituted chalcones as therapeeutic compounds
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
JP3692927B2 (ja) 2000-11-07 2005-09-07 日本電気株式会社 ファクシミリ装置
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
BR0207795A (pt) 2001-03-02 2004-03-23 Hoffmann La Roche Derivados de ácido alcoxicarbonilamino benzóico ou alcoxicarbonilamino tetrazolil fenila como antagonistas de ip
CN1274948C (zh) 2001-05-18 2006-09-13 赫斯工程股份有限公司 用于制造催化式排气净化器的方法和装置
CA2459454A1 (en) 2001-09-14 2003-03-27 Bayer Pharmaceuticals Corporation Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
EP1300403A1 (en) 2001-10-02 2003-04-09 Aventis Pharma S.A. Process for the manufacture of hypoxyxylerone derivatives
GB0123777D0 (en) 2001-10-03 2001-11-21 Cancer Res Ventures Ltd Substituted chalcones as therapeutic agents
GB0123780D0 (en) 2001-10-03 2001-11-21 Cancer Res Ventures Ltd Substituted chalcones as therapeutic agents
US7265096B2 (en) 2002-11-04 2007-09-04 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
EA012844B1 (ru) 2003-02-19 2009-12-30 Йельский Университет Аналоги противовирусных нуклеозидов и способы лечения вирусных инфекций, в частности вич-инфекций
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2005061459A1 (en) 2003-12-04 2005-07-07 Wyeth Biaryl sulfonamides and methods for using same
CA2550299C (en) 2003-12-22 2010-03-30 Christopher R. Roberts Process for fluorocytidine derivatives
EP3075247B1 (en) 2004-02-02 2022-10-12 BioSight Ltd. Conjugates for cancer therapy and diagnosis
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
GB0421294D0 (en) 2004-09-24 2004-10-27 Angiogene Pharm Ltd Bioreductively-activated prodrugs
KR100874052B1 (ko) 2004-12-17 2008-12-12 일라이 릴리 앤드 캄파니 젬시타빈의 아미드 전구약, 그의 조성물 및 그의 용도
EP1676834A1 (en) 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
NO322682B1 (no) 2005-03-18 2006-11-27 Clavis Pharma Asa Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
CA2624726A1 (en) 2005-10-06 2007-04-12 Sanofi-Aventis 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
WO2007117760A2 (en) 2006-02-06 2007-10-18 Dr. Reddy's Laboratories Ltd. Preparation of gemcitabine
US20080182816A1 (en) 2006-02-23 2008-07-31 Tam Joemy C Methods for preparing a novel family of polysaccharride prodrugs for colonic delivery
US20070225248A1 (en) 2006-03-21 2007-09-27 Clavis Pharma As Oral dosage forms of gemcitabine derivatives
GB0722769D0 (en) 2007-11-21 2008-01-02 Biolipox Ab New compounds
EP2136626A4 (en) 2007-03-19 2011-02-23 Oregon State Mannich base n-oxide drugs
CN100475832C (zh) 2007-05-31 2009-04-08 南京卡文迪许生物工程技术有限公司 一种新颖的高立体选择性合成吉西他滨工艺及中间体
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
TWI415858B (zh) 2007-11-06 2013-11-21 Pharmaessentia Corp β-核苷之新穎合成技術
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
US9937128B2 (en) * 2009-08-03 2018-04-10 The University Of North Carolina At Chapel Hill Liposomes comprising a calcium phosphate-containing precipitate
US20130131008A1 (en) * 2011-10-25 2013-05-23 Board Of Regents, The University Of Texas System Lipophilic monophosphorylated derivatives and nanoparticles
CN104955458A (zh) 2012-11-07 2015-09-30 Z·索 取代的吉西他滨芳基酰胺类似物和使用所述类似物的治疗方法
US10000521B2 (en) * 2013-03-15 2018-06-19 Nucorion Pharmaceuticals, Inc. Substituted gemcitabine bicyclic amide analogs and treatment methods using same
WO2015134334A1 (en) * 2014-03-03 2015-09-11 Suo Zucai Gemcitabine analogs
CN105001291B (zh) * 2014-04-15 2018-12-04 上海知萌生物医药科技有限公司 吉西他滨化学传递前药及其制备方法和应用
CN105001191A (zh) * 2015-07-23 2015-10-28 广西师范学院 具有5,2’-二羟基-4’-甲氧基-3-香叶基黄酮骨架的衍生物及其制备方法和用途
US20210380626A1 (en) * 2018-02-02 2021-12-09 Maverix Oncology, Inc. Novel small molecule drug conjugates of gemcitabine derivatives
PE20210367A1 (es) * 2018-02-02 2021-02-26 Maverix Oncology Inc Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina

Similar Documents

Publication Publication Date Title
TWI765640B (zh) 作為dna-pk抑制劑的氨基嘧啶化合物及其衍生物
JP2024023295A (ja) Shp2の活性を阻害するための化合物の製造方法
WO2021248079A1 (en) Heterocyclic compounds and methods of use thereof
WO2021248083A1 (en) Heterocyclic compounds and methods of use thereof
JP2022529166A (ja) 低酸素誘導因子2(アルファ)阻害剤としてのテトラヒドロ-1H-シクロペンタ[cd]インデン誘導体
KR20220107020A (ko) Erk 억제제로서 작용하는 스피로 화합물 및 이의 응용
US20200239480A1 (en) Chemokine receptor modulators and uses thereof
WO2019006359A1 (en) COMPOSITIONS AND METHODS FOR MODULATION OF HAIR GROWTH
EP3906240A1 (en) Compositions and methods for modulating hair growth
WO2019204442A1 (en) K-ras modulators with a cyanoacrylamide moiety
JP2007077162A (ja) アミノシクロヘキシルエーテル化合物およびそれらの用途
EA032094B1 (ru) Дейтерированный палбоциклиб
TWI834127B (zh) 噻吩類化合物及其應用
TW202346293A (zh) 含氮雜環衍生物及其组合物和藥學上的應用
JP2021512951A5 (https=)
WO2017162157A1 (zh) 内磺酰胺化合物及其使用方法
JP2013544270A (ja) 5−メチル−1−(ナフタレン−2−イル)−1h−ピラゾール誘導体
JP3208437B2 (ja) 癌転移抑制剤
JPWO2019152955A5 (https=)
JPWO2019152911A5 (https=)
JP2021512953A5 (https=)
US9862741B2 (en) Cytidine derivative dimers and applications thereof
CN117693517A (zh) 用于靶向治疗肾癌的新型化合物和组合物
JP2008255118A (ja) 抗不整脈薬としてのプリンリボシド
WO2017080313A1 (en) Tetrahydropalmatine derivative, its preparation method and use